Greywolf Therapeutics

📍 Milton, United Kingdom🗓 Founded 2017👥 48 employees💰 Last funded Nov 2024
Biotechnology Research🌐 greywolftherapeutics.com
Website LinkedIn
We want to solve immune dysfunction. Many cancers and other diseases are caused, or resist treatment, because T cells cant recognize or target cells correctly.​ Were progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.​ This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Belgium
1
Frequently asked questions
Who invested in Greywolf Therapeutics?
Greywolf Therapeutics has 1 investors on record on gritt.io and 1 late-stage investors.
When did Greywolf Therapeutics last raise funding?
The most recent investment in Greywolf Therapeutics recorded on gritt.io was in November 2024.
When was Greywolf Therapeutics founded?
Greywolf Therapeutics was founded in 2017.
What industry is Greywolf Therapeutics in?
Greywolf Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Greywolf Therapeutics based?
Greywolf Therapeutics is headquartered in Milton, United Kingdom.